State of the science: Evolving role of surgery for the treatment of ovarian cancer

scientific article published on 29 August 2019

State of the science: Evolving role of surgery for the treatment of ovarian cancer is …
instance of (P31):
scholarly articleQ13442814
editorialQ871232
review articleQ7318358

External links are
P356DOI10.1016/J.YGYNO.2019.08.016
P698PubMed publication ID31472939

P50authorGinger J. GardnerQ91946587
P2093author name stringKara Long Roche
P2860cites workExtracting summary statistics to perform meta-analyses of the published literature for survival endpointsQ27860640
Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer centerQ30717971
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohortQ35262997
Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical OncolQ39669919
Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.Q39902180
A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancerQ40295814
Performance of AGO score for secondary cytoreduction in a high-volume U.S. centerQ40935735
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.Q41721778
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancerQ44461877
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.Q50000120
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.Q53263238
Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian CancerQ57903781
Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinomaQ60685709
Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical TrialQ61900008
Secondary cytoreduction for ovarian cancer following cisplatin therapyQ70590731
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trialQ79158185
Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian CancerQ90869406
Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?Q91045719
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian NeoplasmsQ91967950
P433issue1
P921main subjectovarian cancerQ172341
P304page(s)3-7
P577publication date2019-08-29
P1433published inGynecologic OncologyQ5625182
P1476titleState of the science: Evolving role of surgery for the treatment of ovarian cancer
P478volume155

Reverse relations

Q96228870A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiativecites workP2860

Search more.